Stockholm 9th July 2018 - Peptonic Medical AB (publ) (’Peptonic’) or (’Company’) today announced that VagiVital® now can be purchased via its webshop on www.vagivital.se . VagiVital® is Peptonic’s hormone-free self-care product for the treatment of symptoms associated with vaginal atrophy. The product has been tested in clinical studies with excellent results. The clinical studies have been carried out at Karolinska Hospital in Huddinge, Akademiska Universitetssjukhuset in Upsala and Norrlands Universitetssjukhus in Umeå, Sweden.
- This is a historical event in Peptonic. Since the day we saw the results of the clinical study in March 2017 we have been aiming for launching VagiVital®. Now this moment has arrived and we are very proud and pleased about that, says Johan Inborr, CEO of Peptonic Medical. We can now offer a safe and effective treatment to all women suffering from vaginal dryness.
For more information, please contact;
Johan Inborr, CEO
Mobile: +46 708 853 893
This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9 July 2018.
VagiVital® is a hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects.
Peptonic Medical is launching VagiVital® as a non-prescription self-care product in 2018.
About Peptonic Medical
Peptonic Medical is an innovative Swedish development company. Our vision is to offer safe and effective treatments for women suffering from vaginal atrophy during menopause and after.
VagiVital® is a trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy.
The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.
In July 2014, Peptonic Medical was listed on the AktieTorget stock exchange (www.aktietorget.se, ticker: PMED) in Stockholm.
For more information: www.peptonicmedical.com